Literature DB >> 25388215

Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma.

Aparna Kailasam1, Sumeet K Mittal1, Devendra K Agrawal1.   

Abstract

Epigenetic influences, such as DNA methylation, histone acetylation, and up-regulation/down-regulation of genes by microRNAs, change the genetic makeup of an individual without affecting DNA base-pair sequences. Indeed, epigenetic changes play an integral role in the progression from normal esophageal mucosa to Barrett's esophagus to esophageal adenocarcinoma via dysplasia-metaplasia-neoplasia sequence. Many genes involved in esophageal adenocarcinoma display hypermethylation, leading to their down-regulation. The classes of these genes include cell cycle control, DNA and growth factor repair, tumor suppressors, antimetastasis, Wnt-related genes, and proapoptotic genes. Histone acetylation in the pathophysiology of esophageal diseases has not been thoroughly investigated, and its critical role in the development of esophageal adenocarcinoma is less defined. Many microRNAs have been associated with the development of Barrett's esophagus and esophageal adenocarcinoma. Here, we critically addressed the specific steps most closely influenced by microRNAs in the progression from Barrett's esophagus to esophageal adenocarcinoma. However, microRNAs can target up to hundreds of genes, making it difficult to correlate directly with a given phenotype of the disease. Esophageal adenocarcinoma progressing from premalignant condition of Barrett's esophagus carries an extremely poor prognosis. Risk stratification for patients based on their epigenetic profiles may be useful in providing more targeted and directed treatment to patients.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Barrett's esophagus; DNA methylation; epigenetics; esophageal adenocarcinoma; esophageal squamous cell carcinoma; histone acetylation; miRNA

Mesh:

Substances:

Year:  2014        PMID: 25388215      PMCID: PMC4429045          DOI: 10.1111/cts.12242

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  77 in total

1.  Role of NADPH oxidase NOX5-S, NF-κB, and DNMT1 in acid-induced p16 hypermethylation in Barrett's cells.

Authors:  Jie Hong; Dan Li; Jack Wands; Rhonda Souza; Weibiao Cao
Journal:  Am J Physiol Cell Physiol       Date:  2013-09-11       Impact factor: 4.249

Review 2.  Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Yu Fang; Xiaoxin Chen; Manisha Bajpai; Amit Verma; Kiron M Das; Rhonda F Souza; Katherine S Garman; Claire L Donohoe; Naoimh J O'Farrell; John V Reynolds; Katerina Dvorak
Journal:  Ann N Y Acad Sci       Date:  2013-10       Impact factor: 5.691

Review 3.  Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.

Authors:  Yoshifumi Baba; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2013-01-05       Impact factor: 2.549

4.  Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.

Authors:  Kenji Makita; Riko Kitazawa; Shuho Semba; Koto Fujiishi; Miku Nakagawa; Ryuma Haraguchi; Sohei Kitazawa
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

5.  MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.

Authors:  Dipen M Maru; Rajesh R Singh; Christina Hannah; Constance T Albarracin; Yong X Li; Ronald Abraham; Angela M Romans; Hui Yao; Madan G Luthra; Sharmila Anandasabapathy; Stephen G Swisher; Wayne L Hofstetter; Asif Rashid; Rajyalakshmi Luthra
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

Review 6.  Reflux, Barrett's oesophagus and adenocarcinoma: burning questions.

Authors:  Christopher P Wild; Laura J Hardie
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

7.  Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas.

Authors:  Dunfa Peng; Tian-Ling Hu; Aixiang Jiang; Mary Kay Washington; Christopher A Moskaluk; Regine Schneider-Stock; Wael El-Rifai
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

8.  The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.

Authors:  R Banerjee; R-S Mani; N Russo; C S Scanlon; A Tsodikov; X Jing; Q Cao; N Palanisamy; T Metwally; R C Inglehart; S Tomlins; C Bradford; T Carey; G Wolf; S Kalyana-Sundaram; A M Chinnaiyan; S Varambally; N J D'Silva
Journal:  Oncogene       Date:  2011-05-02       Impact factor: 9.867

Review 9.  Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma.

Authors:  Ji-Sheng Li; Jian-Ming Ying; Xiu-Wen Wang; Zhao-Hui Wang; Qian Tao; Li-Li Li
Journal:  Chin J Cancer       Date:  2012-05-08

10.  Pathological characteristics of esophageal cancer.

Authors:  Hong-Yun Shi; Shu-Chai Zhu; Wen-Bin Shen; Miao-Ling Liu
Journal:  Oncol Lett       Date:  2014-06-04       Impact factor: 2.967

View more
  10 in total

Review 1.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Authors:  Ravindran Caspa Gokulan; Monica T Garcia-Buitrago; Alexander I Zaika
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

2.  Promoter methylation and expression of Raf kinase inhibitory protein in esophageal squamous cell carcinoma.

Authors:  Hong Wei; Zhijun Liu; Hongyan She; Baoguo Liu; Junxia Gu; Dongmin Wei; Xiangyang Zhang; Jiufeng Wang; Shujing Qi; Fumin Ping
Journal:  Oncol Lett       Date:  2017-01-18       Impact factor: 2.967

Review 3.  Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review.

Authors:  Sumeet K Mittal; Joe Abdo; Malika P Adrien; Binyam A Bayu; Jay R Kline; Molly M Sullivan; Devendra K Agrawal
Journal:  J Gastrointest Oncol       Date:  2021-08

Review 4.  Emerging therapeutic targets in esophageal adenocarcinoma.

Authors:  Puja Gaur; Clayton R Hunt; Tej K Pandita
Journal:  Oncotarget       Date:  2016-07-26

5.  Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes.

Authors:  Joe Abdo; Carrie A Bertellotti; David L Cornell; Devendra K Agrawal; Sumeet K Mittal
Journal:  Front Oncol       Date:  2017-07-18       Impact factor: 6.244

6.  "Targeted" Chemotherapy for Esophageal Cancer.

Authors:  Joe Abdo; Devendra K Agrawal; Sumeet K Mittal
Journal:  Front Oncol       Date:  2017-04-03       Impact factor: 6.244

7.  Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.

Authors:  Anna V Gaponova; Alexander Y Deneka; Tim N Beck; Hanqing Liu; Gregory Andrianov; Anna S Nikonova; Emmanuelle Nicolas; Margret B Einarson; Erica A Golemis; Ilya G Serebriiskii
Journal:  Oncotarget       Date:  2017-03-21

Review 8.  LONG-NONCODING RNAs in gastroesophageal cancers.

Authors:  Giuseppe Nicolò Fanelli; Pierluigi Gasparini; Irene Coati; Ri Cui; Hubert Pakula; Basudev Chowdhury; Nicola Valeri; Fotios Loupakis; Juozas Kupcinskas; Rocco Cappellesso; Matteo Fassan
Journal:  Noncoding RNA Res       Date:  2018-11-01

9.  CENPE expression is associated with its DNA methylation status in esophageal adenocarcinoma and independently predicts unfavorable overall survival.

Authors:  Xueqiang Zhu; Xing Luo; Gang Feng; Hui Huang; Yangke He; Wen Ma; Changqing Zhang; Ming Zeng; Hao Liu
Journal:  PLoS One       Date:  2019-02-04       Impact factor: 3.240

Review 10.  Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers.

Authors:  Adam Barsouk; Prashanth Rawla; Andreas V Hadjinicolaou; John Sukumar Aluru; Alexander Barsouk
Journal:  Med Sci (Basel)       Date:  2019-09-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.